Presented by expert speakers, our workshops will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the workshop recording afterwards.
Formulation & Delivery Digital Workshop
Nanotechnology For Emerging Therapeutics
Mon, June 8, 2020 14:00 PM - 15.15 PM BST
Join Professor Dobson as we discuss the science of nanotechnology fundamentally changing drug transport and targeting with novel material therapies.
Presentation 1: How will Nanotechnology contribute towards Therapeutics? Peter Dobson (15 Mins)
Presentation 2: Oral Insulin Silica Nanoparticles, David Brayden (15 Mins)
Presentation 3: Microfluidic preparation of drug-loaded liposomes, Dimitrios Lamprou (15 mins)
Panel Discussion: (30 mins)
Peter Dobson, Professor, University of Oxford
Dimitrios Lamprou, Reader in Pharmaceutical Engineering, Queen’s University Belfast
David Brayden, Professor Of Advanced Drug Delivery, University College Dublin
Inhalation & Respiratory Drug Delivery Webinars
Inhaled Targeted-Inhibition Of Galectin-3 Dose Dependently Blocks Plasma Biomarkers In Patients With Idiopathic Pulmonary Fibrosis
Tue, Mar 3, 2020 2:00 PM - 3:00 PM GMT
Presented by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca
Hosted by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca
- Galectin-3 is a key regulator of fibrosis
- TD-139 is a specific Galectin-3 inhibitor formulated for inhaled treatment
- TD139 is safe and well tolerated in man
- TD-139 demonstrated dose dependent target engagement
- TD-139 specifically decreases in plasma biomarkers associated with IPF progression
- Suggesting inhaled TD-139 is a potential novel therapy for IPF
Our complimentary webinar is for respiratory and inhalation experts interested in learning more about the latest innovations in inhaled therapies. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Professor Tariq Sethi is Chief Physician Scientist, Vice President AstraZeneca and Emeritus Professor of Respiratory Medicine Kings College London. He was previous head of the Respiratory Immunology Autoimmunity Translational Medicine Unit. Prior to joining AZ he was Head of Respiratory Medicine at Guy’s, St. Thomas’ and King’s College Hospital NHS Foundation Trusts and Professor of Respiratory Medicine King’s College London and formally Professor at the University of Edinburgh. He was educated at Cambridge and London Universities followed by hospital jobs in London. He did a Ph.D at the Imperial Cancer Research Fund London, was an MRC Travelling Fellow at the Scripps Research Institute California and a Wellcome Trust Senior Research Leave Fellow in Edinburgh. His research interests focus on the interaction between inflammation and lung cancer, Prof. Sethi continues on the editorial board of THORAX and was formally a member of the Population Systems Medicine Board Medical Research Council UK, Chair of Asthma (UK) and member of the British Lung Foundation Scientific Committees. He is also a Co-Founder of Galecto Biotech